NASDAQ:SCPH scPharmaceuticals - SCPH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding scPharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $8.76 +0.23 (+2.70%) (As of 03/27/2023 04:00 PM ET) Add Compare Share Share Today's Range$8.36▼$9.1850-Day Range$5.59▼$9.4752-Week Range$3.68▼$10.38Volume337,091 shsAverage Volume546,227 shsMarket Capitalization$240.29 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaSustainability scPharmaceuticals MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside98.5% Upside$18.00 Price TargetShort InterestBearish17.45% of Float Sold ShortDividend StrengthN/ASustainability-0.90Upright™ Environmental ScoreNews Sentiment0.29Based on 16 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.58) to ($1.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.00 out of 5 starsMedical Sector398th out of 995 stocksPharmaceutical Preparations Industry181st out of 482 stocks 3.5 Analyst's Opinion Consensus RatingscPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $18.00, scPharmaceuticals has a forecasted upside of 98.5% from its current price of $9.07.Amount of Analyst CoveragescPharmaceuticals has only been the subject of 2 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted17.45% of the float of scPharmaceuticals has been sold short.Short Interest Ratio / Days to CoverscPharmaceuticals has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in scPharmaceuticals has recently increased by 3.83%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldscPharmaceuticals does not currently pay a dividend.Dividend GrowthscPharmaceuticals does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorescPharmaceuticals has received a 72.87% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.Environmental SustainabilityThe Environmental Impact score for scPharmaceuticals is -0.90. Previous Next 1.8 News and Social Media Coverage News SentimentscPharmaceuticals has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 16 news articles for scPharmaceuticals this week, compared to 2 articles on an average week.Search InterestOnly 18 people have searched for SCPH on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, scPharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.70% of the stock of scPharmaceuticals is held by insiders.Percentage Held by Institutions53.90% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for scPharmaceuticals are expected to grow in the coming year, from ($1.58) to ($1.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of scPharmaceuticals is -6.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of scPharmaceuticals is -6.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioscPharmaceuticals has a P/B Ratio of 4.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About scPharmaceuticals (NASDAQ:SCPH) StockscPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. Its products include FUROSCIX, a furosemide injection which is used as parenteral diuretic in treating heart failure and scCeftriaxone, used as parenteral antibiotic outside the hospital setting. The company was founded by Pieter Muntendam and Bertram Pitt in February 2013 and is headquartered in Burlington, MA.Read More Receive SCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SCPH Stock News HeadlinesMarch 27, 2023 | finance.yahoo.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2022 Earnings Call TranscriptMarch 26, 2023 | americanbankingnews.comHead to Head Comparison: scPharmaceuticals (NASDAQ:SCPH) vs. Calithera Biosciences (NASDAQ:CALA)March 27, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 24, 2023 | finance.yahoo.comWhen Will scPharmaceuticals Inc. (NASDAQ:SCPH) Turn A Profit?March 24, 2023 | americanbankingnews.comscPharmaceuticals Inc. (NASDAQ:SCPH) Expected to Post FY2025 Earnings of $0.12 Per ShareMarch 24, 2023 | americanbankingnews.comscPharmaceuticals (NASDAQ:SCPH) Receives "Buy" Rating from HC WainwrightMarch 22, 2023 | finance.yahoo.comscPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Business UpdateMarch 15, 2023 | finance.yahoo.comscPharmaceuticals to Announce Fourth Quarter and Full-Year 2022 Financial Results on Wednesday, March 22March 27, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.February 23, 2023 | finance.yahoo.comscPharmaceuticals to Participate in the Cowen 43rd Annual Health Care ConferenceFebruary 21, 2023 | finance.yahoo.comscPharmaceuticals Announces Launch and Commercial Availability of FUROSCIX® (furosemide injection)February 13, 2023 | marketwatch.com2023-2027 Large Volume Wearable Injectors Market Size which includes Competitor Analysis and Market Dynamic Forecast | 98 PagesFebruary 6, 2023 | finance.yahoo.comscPharmaceuticals Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 31, 2023 | finance.yahoo.comscPharmaceuticals to Participate in the SVB Securities Global Biopharma ConferenceJanuary 30, 2023 | finance.yahoo.comscPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial UpdateJanuary 10, 2023 | finance.yahoo.comscPharmaceuticals Inc. (NASDAQ:SCPH) stock most popular amongst private equity firms who own 41%, while individual investors hold 36%December 20, 2022 | finance.yahoo.comWhat Makes scPharmaceuticals, Inc. (SCPH) a New Buy StockDecember 20, 2022 | finance.yahoo.comHas scPharmaceuticals (SCPH) Outpaced Other Medical Stocks This Year?December 19, 2022 | finance.yahoo.comscPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial OfficerDecember 14, 2022 | finance.yahoo.comscPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access EventNovember 29, 2022 | 247wallst.comOrin Hirschman Discloses Position in SCPH / scPharmaceuticalsNovember 22, 2022 | finance.yahoo.comscPharmaceuticals Announces Pricing of $50 Million Public OfferingNovember 22, 2022 | finance.yahoo.comscPharmaceuticals Announces Proposed Underwritten Public Offering of Common StockNovember 9, 2022 | finance.yahoo.comscPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business UpdateNovember 2, 2022 | finance.yahoo.comscPharmaceuticals to Participate in the Jefferies London Healthcare ConferenceOctober 26, 2022 | finance.yahoo.comscPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022October 20, 2022 | seekingalpha.comscPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients - Seeking AlphaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SCPH Company Calendar Last Earnings3/22/2023Today3/27/2023Next Earnings (Estimated)5/15/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SCPH CUSIPN/A CIK1604950 Webwww.scpharma.com Phone(617) 517-0730FaxN/AEmployees26Year FoundedN/APrice Target and Rating Average Stock Price Forecast$18.00 High Stock Price Forecast$25.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+111.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,030,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-76.19% Return on Assets-49.01% Debt Debt-to-Equity Ratio0.51 Current Ratio16.63 Quick Ratio2.75 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.06 per share Price / Book4.14Miscellaneous Outstanding Shares27,430,000Free Float26,145,000Market Cap$233.98 million OptionableNot Optionable Beta0.22 Key ExecutivesJohn H. TuckerPresident, Chief Executive Officer & DirectorRachael NokesTreasurer, Chief Financial & Accounting OfficerJohn MohrSenior VP-Clinical Development & Medical AffairsMike HassmanSenior Vice President-Technical OperationsKatherine TaudvinDirector-IR & Corporate DevelopmentKey CompetitorsAnnexonNASDAQ:ANNXAstria TherapeuticsNASDAQ:ATXSZevra TherapeuticsNASDAQ:ZVRAUroGen PharmaNASDAQ:URGNOptiNoseNASDAQ:OPTNView All CompetitorsInsiders & InstitutionsAIGH Capital Management LLCBought 1,793,171 shares on 2/16/2023Ownership: 9.297%Morgan StanleyBought 55,689 shares on 2/15/2023Ownership: 0.543%Jane Street Group LLCBought 59,313 shares on 2/15/2023Ownership: 0.216%Man Group plcBought 20,430 shares on 2/15/2023Ownership: 0.074%Boothbay Fund Management LLCSold 26,798 shares on 2/15/2023Ownership: 0.051%View All Insider TransactionsView All Institutional Transactions SCPH Stock - Frequently Asked Questions Should I buy or sell scPharmaceuticals stock right now? 6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SCPH shares. View SCPH analyst ratings or view top-rated stocks. What is scPharmaceuticals' stock price forecast for 2023? 6 brokers have issued twelve-month price targets for scPharmaceuticals' stock. Their SCPH share price forecasts range from $13.00 to $25.00. On average, they predict the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 111.0% from the stock's current price. View analysts price targets for SCPH or view top-rated stocks among Wall Street analysts. How have SCPH shares performed in 2023? scPharmaceuticals' stock was trading at $7.17 on January 1st, 2023. Since then, SCPH shares have increased by 19.0% and is now trading at $8.53. View the best growth stocks for 2023 here. When is scPharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 15th 2023. View our SCPH earnings forecast. How were scPharmaceuticals' earnings last quarter? scPharmaceuticals Inc. (NASDAQ:SCPH) announced its earnings results on Wednesday, March, 22nd. The company reported ($0.30) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.12. What ETFs hold scPharmaceuticals' stock? ETFs with the largest weight of scPharmaceuticals (NASDAQ:SCPH) stock in their portfolio include AdvisorShares Dorsey Wright Micro-Cap ETF (DWMC). What other stocks do shareholders of scPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX). When did scPharmaceuticals IPO? (SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. What is scPharmaceuticals' stock symbol? scPharmaceuticals trades on the NASDAQ under the ticker symbol "SCPH." Who are scPharmaceuticals' major shareholders? scPharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (9.30%), Armistice Capital LLC (7.83%), RA Capital Management L.P. (6.77%), Millennium Management LLC (3.01%), Dimensional Fund Advisors LP (0.78%) and Renaissance Technologies LLC (0.77%). Insiders that own company stock include 5Am Partners Iv, Llc, Andrew J Schwab, Jack A Khattar, John H Tucker and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of scPharmaceuticals? Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is scPharmaceuticals' stock price today? One share of SCPH stock can currently be purchased for approximately $8.53. How much money does scPharmaceuticals make? scPharmaceuticals (NASDAQ:SCPH) has a market capitalization of $233.98 million. The company earns $-28,030,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. How can I contact scPharmaceuticals? scPharmaceuticals' mailing address is 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA, 01830. The official website for the company is www.scpharma.com. The company can be reached via phone at (617) 517-0730 or via email at tignelzi@scpharma.com. This page (NASDAQ:SCPH) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.